Effects of combined oral contraceptives on hemostasis in women of late reproductive age
- 作者: Tarasova M.A.1, Ryabceva I.T.1, Grigorieva V.A.1, Shapovalova K.A.1
-
隶属关系:
- I.P. Pavlov State Medical University
- 期: 卷 48, 编号 5S (1999)
- 页面: 157-157
- 栏目: Articles
- ##submission.dateSubmitted##: 22.02.2022
- ##submission.dateAccepted##: 22.02.2022
- ##submission.datePublished##: 15.12.1999
- URL: https://journals.eco-vector.com/jowd/article/view/101455
- DOI: https://doi.org/10.17816/JOWD101455
- ID: 101455
如何引用文章
全文:
详细
Objective: To investigate the effects of combined oral contraceptives (COCs) on hemostasis in women of late reproductive and perimenopausal age.
全文:
Objective: to investigate the effects of combined oral contraceptives (COCs) on hemostasis in women of late reproductive and perimenopausal age.
Methods: 64 women within the age interval of 35-49 years were accepted to the study. Three different formulations of COCs were used: 20 g ethinylestradiol with 150 g desogestrel, 30 g ethinylestrad with 150 g desogestrel and 30 g ethinylestradiol with 300 g norgestrel. 13 different parameters of hemostasis including resistance to activated protein C (APC resistance) and presence of Lupus anticoagulant were evaluated at the commencement of the study and after 2 and 6 cycles of COCs intake. The presence of Lupus anticoagulant was detected using tissue thromboplastin inhibition test. Test for identification of the factor V Leiden mutation based on polymerize chain reaction (PCR) was performed as well.
Results: There was a significant reduction of APC-ratio in heterozygous carriers of factor V Leiden as compared to women without this mutation (2,1±0,1 and 2,7±0,1; p<0,01). The presence of lupus anticoagulant was identified more frequently in women with the factor V Leiden mutation using COCs (p,0,01). There was a significant reduction of APC-ratio in these women as well (1,7±0,1 and 2,1±0,1; p<0,01). APC resistance was diagnosed in 3,1% of the participants without the factor V Leiden mutation before the treatment and in 14,1% - after COCs use (p<0,05). The prevalence of APC-resistance was higher in COC users with Lupus anticoagulant as compared to those without this anticoagulant (25,0% - 8,7%, p<0,05).
Conclusions: Apparently APS-resistance and Lupus anticoagulant may be involved in the development of thrombophilia associated with COC use.
作者简介
M. Tarasova
I.P. Pavlov State Medical University
编辑信件的主要联系方式.
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg
I. Ryabceva
I.P. Pavlov State Medical University
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg
V. Grigorieva
I.P. Pavlov State Medical University
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg
K. Shapovalova
I.P. Pavlov State Medical University
Email: info@eco-vector.com
俄罗斯联邦, St. Petersburg